Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease. Its lead product candidates include KD025, an inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical studies for the treatment of chronic graft-versus-host, fibrotic, and psoriasis diseases; ROCK inhibitor platform, a rho-associated coiled-coil kinase inhibitor, which is in preclinical development to treat specific fibrotic and neurodegenerative diseases; and KD034, a generic formulation of trientine hydrochloride for the treatment of Wilson's disease, a genetic liver disease. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease (PKD) and autosomal recessive PKD. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Symphony Evolution, Inc.; Nano Terra, Inc.; Dyax Corp.; Chiromics, LLC; MeiraGTx Limited; AbbVie Inc.; Zydus Pharmaceuticals USA, Inc.; Jinghua Pharmaceutical Group Co., Ltd.; and Camber Pharmaceuticals, Inc. The company is headquartered in New York, New York.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:KDMN
Previous Symbol
CUSIPN/A
Phone212-308-6000
Debt
Debt-to-Equity Ratio0.32
Current Ratio6.64
Quick Ratio3.08
Price-To-Earnings
Trailing P/E Ratio-1.79
Forward P/E Ratio-2.70
P/E GrowthN/A
Sales & Book Value
Annual Sales$12.26 million
Price / Sales23.43
Cash FlowN/A
Price / CashN/A
Book Value$0.76 per share
Price / Book3.34
Profitability
EPS (Most Recent Fiscal Year)($1.42)
Net Income$-79,770,000.00
Net Margins-1,176.75%
Return on Equity-253.82%
Return on Assets-55.79%
Miscellaneous
Employees101
Outstanding Shares113,100,000
Market Cap$277.10 million
OptionableOptionable
Kadmon (NYSE:KDMN) Frequently Asked Questions
What is Kadmon's stock symbol?
Kadmon trades on the New York Stock Exchange (NYSE) under the ticker symbol "KDMN."
How were Kadmon's earnings last quarter?
Kadmon Holdings Inc (NYSE:KDMN) posted its quarterly earnings results on Thursday, August, 9th. The company reported $0.24 EPS for the quarter, beating the Zacks' consensus estimate of ($0.26) by $0.50. The business earned $0.36 million during the quarter, compared to the consensus estimate of $0.90 million. Kadmon had a negative return on equity of 253.82% and a negative net margin of 1,176.75%. View Kadmon's Earnings History.
When is Kadmon's next earnings date?
What price target have analysts set for KDMN?
4 brokers have issued 1-year price objectives for Kadmon's shares. Their predictions range from $2.90 to $25.00. On average, they anticipate Kadmon's share price to reach $13.2250 in the next twelve months. This suggests a possible upside of 420.7% from the stock's current price. View Analyst Price Targets for Kadmon.
What is the consensus analysts' recommendation for Kadmon?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kadmon in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kadmon.
What are Wall Street analysts saying about Kadmon stock?
Here are some recent quotes from research analysts about Kadmon stock:
- 1. HC Wainwright analysts commented, "Our price target of $25 is based on a probability adjusted sum-of-parts $12 from KD025 in cGVHD + $12 from tesevatinib in PKD + $1 cash. Risks to our investment thesis and target price include: (1) failure in clinical trials; (2) failure to secure regulatory approvals; and (3) a smaller than anticipated commercial opportunity due to market sizing, competition, and pricing. Kadmon Holdings, Inc." (11/12/2018)
- 2. According to Zacks Investment Research, "Kadmon Holdings, Inc. is a biopharmaceutical company. It engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. Kadmon Holdings, Inc. is headquartered in New York. " (10/11/2018)
Has Kadmon been receiving favorable news coverage?
News coverage about KDMN stock has been trending negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Kadmon earned a news sentiment score of -2.1 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near term.
Who are some of Kadmon's key competitors?
Some companies that are related to Kadmon include Retrophin (RTRX), Rhythm Pharmaceuticals (RYTM), Zai Lab (ZLAB), Intra-Cellular Therapies (ITCI), Amphastar Pharmaceuticals (AMPH), Kiniksa Pharmaceuticals (KNSA), Alder Biopharmaceuticals (ALDR), Uniqure (QURE), Lexicon Pharmaceuticals (LXRX), Viking Therapeutics (VKTX), Revance Therapeutics (RVNC), Aptinyx (APTX), Akorn (AKRX), Puma Biotechnology (PBYI) and ImmunoGen (IMGN).
Who are Kadmon's key executives?
Kadmon's management team includes the folowing people:
- Dr. Harlan W. Waksal, Pres, CEO & Director (Age 65)
- Mr. Konstantin Poukalov, Exec. VP, CFO & Principal Accounting Officer (Age 34)
- Mr. Steven N. Gordon, Chief Admin., Compliance & Legal Officer, Exec. VP & Gen. Counsel (Age 50)
- Dr. John L. Ryan, Chief Medical Officer & Exec. VP (Age 75)
- Wei Chen Ph.D., Associate Director of Immunology
When did Kadmon IPO?
(KDMN) raised $101 million in an initial public offering (IPO) on Wednesday, July 27th 2016. The company issued 5,600,000 shares at a price of $16.00-$20.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.
Who are Kadmon's major shareholders?
Kadmon's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Acuta Capital Partners LLC (6.54%), BlackRock Inc. (5.98%), VHCP Management III LLC (2.11%), Renaissance Technologies LLC (0.29%), Asymmetry Capital Management L.P. (0.29%) and Bank of New York Mellon Corp (0.26%). Company insiders that own Kadmon stock include Daniel S Loeb, Eugene Bauer, Goldentree Asset Management Lp, Harlan Waksal and Steven N Gordon. View Institutional Ownership Trends for Kadmon.
Which institutional investors are selling Kadmon stock?
Which institutional investors are buying Kadmon stock?
KDMN stock was purchased by a variety of institutional investors in the last quarter, including VHCP Management III LLC, BlackRock Inc., Bank of New York Mellon Corp, Renaissance Technologies LLC, Dimensional Fund Advisors LP, Wells Fargo & Company MN and American International Group Inc.. Company insiders that have bought Kadmon stock in the last two years include Daniel S Loeb, Eugene Bauer, Harlan Waksal and Steven N Gordon. View Insider Buying and Selling for Kadmon.
How do I buy shares of Kadmon?
Shares of KDMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kadmon's stock price today?
One share of KDMN stock can currently be purchased for approximately $2.54.
How big of a company is Kadmon?
Kadmon has a market capitalization of $277.10 million and generates $12.26 million in revenue each year. The company earns $-79,770,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis. Kadmon employs 101 workers across the globe.
What is Kadmon's official website?
How can I contact Kadmon?
Kadmon's mailing address is 450 East 29th Street, New York NY, 10016. The company can be reached via phone at 212-308-6000 or via email at [email protected]
MarketBeat Community Rating for Kadmon (NYSE KDMN)
MarketBeat's community ratings are surveys of what our community members think about Kadmon and other stocks. Vote "Outperform" if you believe KDMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KDMN will underperform the S&P 500 over the long term. You may vote once every thirty days.
